In glioblastoma, EGFR variant III, ERBB2/HER2, and IL-13 receptor α2 (IL13Rα2) are important CAR-T cell therapy targets that have been investigated in many clinical trial studies [212]. Here, ERBB2 is linked to glioblastoma.